MedCity News’ Brandon Glenn breaks down the recent FDA approval of Meridian Bioscience’s pediatric version of its C. difficile test on this week’s edition of Health Journal on ONN. Meridian said its new product is the only C. difficile test that the U.S. Food and Drug Administration has cleared for use on children under the […]
Diagnostics company Meridian Bioscience (NASDAQ: VIVO) has received federal regulatory clearance to begin selling a pediatric version of its C. difficile test. An earlier version of the test, which the company calls the "illumigene," was cleared for commercialization by the FDA in July. However, that clearance didn't apply to children.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Life science diagnostic testing company Meridian Bioscience had a strong 2010 as swine flu fears pushed up demand for its rapid flu tests. But without swine flu, Meridian announced a 32 percent decrease in the diagnostic test maker's first-quarter earnings for fiscal 2011.
It happened to diagnostic test maker Meridian Bioscience Inc. (NASDAQ:VIVO), but at least it doesn't appear to have caused any damage. Meridian was victimized by a Twitter "name squatter." That is, someone not affiliated with the company created a Twitter account using its name, logo and references to its website.
Diagnostic test maker Meridian Bioscience Inc. (NASDAQ:VIVO) capped a "disappointing" fiscal 2010 with fourth-quarter profits that fell below Wall Street's expectations and sent its shares tumbling.
Meridian Bioscience Inc. (NASDAQ:VIVO) has obtained a license to begin selling its illumigene C. difficile molecular test in Canada.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
For fiscal 2011, Meridian expects earnings between 77 cents and 82 cents per diluted share, and sales between $165 million and $170 million.
Cincinnati, Ohio life sciences company Meridian Bioscience Inc. (NASDAQ: VIVO) has acquired the outstanding capital stock of Bioline Ltd., the London, England-based maker and distributor of molecular biology reagents, for $23.3 million in cash. Meridian Bioscience also said Tuesday its profits fell 24 percent in the fiscal third quarter from a year ago, while sales […]
Diagnostics company Meridian Bioscience Inc. (NASDAQ: VIVO) has received the go-ahead from the Food and Drug Administration to sell its first molecular test — illumigene C. difficile. Over the years the Cincinnati life science company has gotten good at making diagnostic test kits that detect bugs like C. difficile, which is a bacterium that can […]
Meridian Bioscience Inc. (NASDAQ: VIVO) has struck an exclusive, world-wide product development and distribution agreement with an Italian diagnostics company that is likely to open doors to new customers in Eastern Europe and Asia. The agreement with DiaSorin S.p.A. of Vercelli, Italy, is a turnabout for Cincinnati, Ohio, diagnostic kit maker Meridian, said Todd Morrow, […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Meridian Bioscience has filed an application for federal regulatory approval of a next-generation molecular test that detects a type of bacteria that causes damage to the digestive system. Meridian’s illumigene test is designed to find traces of C. difficile, a bacteria that can cause life-threatening inflammation of the colon and most often affects elderly people […]
Updated 4:34 p.m. Shares of Meridian Bioscience Inc. rebounded a bit Thursday–a day after the Cincinnati diagnostic test maker cut its sales and earnings outlook for the fiscal year ending in September, sending its shares down 15 percent. Meridian shares rose 50 cents, or 2.5 percent, to $20.58 Thursday on the Nasdaq Stock Market. On […]
Wright State University in Dayton plans to build a $22 million state-of-the-art center to make the university a national leader in neuroscience research, and Premier Health Partners plans to provide $4.3 million over five years to create a department of neurology at Wright State’s Boonshoft School of Medicine, according to the Dayton Daily News.
Over the years, Meridian Bioscience Inc. has gotten good at making diagnostic test kits that detect bugs like C. difficile and H. pylori, both bacteria that can wreak havoc in the digestive tract -- or worse. Now, the longtime Cincinnati life sciences company is getting into molecular testing.
Meridian Bioscience Inc. reported record revenue and net income for its fiscal first quarter, despite increased competition for sales of C. difficile test kits. The Cincinnati company has been working on an answer to growing C. difficile test competition: illumigene.